Eloralintide Clinical Trials: Every Registered Study, Phase 1 to Phase 3 (October 2026)
Research use only. This guide is education, not medical advice or a recruitment notice. Eloralintide is an investigational drug that no regulator has approved. Whether to join any clinical trial is a decision for you and your clinician, and Peptryn gives no dosing or administration guidance.
Short answer: As of October 15, 2026, ClinicalTrials.gov lists 21 Eli Lilly studies of eloralintide (LY3841136): 11 phase 1, 5 phase 2 and 5 phase 3, covering about 9,243 participants actual and planned. Seven are completed, three are active but not recruiting and eleven are recruiting. The five phase 3 ENLIGHTEN studies test eloralintide in obesity without diabetes, obesity with type 2 diabetes, sleep apnea, knee osteoarthritis pain and obesity that persists on a weekly incretin drug. Only the first-in-human study, the phase 2 trial and the EloraTZP phase 2b trial have reported results.
Key takeaways
- 21 registered studies, all sponsored by Eli Lilly: 11 phase 1, 5 phase 2, 5 phase 3.
- Phase 3 is five studies with 5,615 planned participants. Estimated primary completion runs from January 2028 (ENLIGHTEN-2) to June 2028 (ENLIGHTEN-6).
- Specialist studies are running in liver and kidney impairment, Japanese and Chinese participants and women, which will shape any label.
- Two phase 2 studies pair eloralintide with a second Lilly drug, macupatide (LY3532226), and a third phase 2 study tests eloralintide with tirzepatide (EloraTZP, finished).
- Phase 3 studies list 115 to 185 research sites each, and all enroll adults aged 18 and over.
- Registry dates are estimates and change. This page is a snapshot from the ClinicalTrials.gov API on October 15, 2026.
Last verified October 15, 2026. Sources are listed at the end. For laboratory and research use only. Nothing here is medical or legal advice.
Contents
- The program in numbers
- Phase 3: the ENLIGHTEN program
- Phase 2: five studies
- Phase 1: eleven studies
- Which studies have published results
- How to read a registry entry
- How people find eloralintide trials
- What is missing from the registry
- What to expect next
- Common questions
The program in numbers
| Phase 1 | Phase 2 | Phase 3 | Total | |
|---|---|---|---|---|
| Registered studies | 11 | 5 | 5 | 21 |
| Participants (actual plus planned) | 917 | 2,711 | 5,615 | 9,243 |
| Completed | 5 | 2 | 0 | 7 |
| Active, not recruiting | 2 | 1 | 0 | 3 |
| Recruiting | 4 | 2 | 5 | 11 |
The phase 2 total includes a multi-drug master protocol (LY900038, 1,481 planned participants) in which eloralintide is one of several investigational appendices, so the eloralintide-specific number is smaller. The counts come from a search of the registry for the code LY3841136, which finds records filed under that name.
Phase 3: the ENLIGHTEN program
| Study | NCT number | Population | Participants | Status | Started | Primary completion |
|---|---|---|---|---|---|---|
| ENLIGHTEN-2 | NCT07282600 | Obesity or overweight with type 2 diabetes | 1,035 (est.) | Recruiting | Dec 2025 | Jan 2028 |
| ENLIGHTEN-1 | NCT07321886 | Obesity or overweight without diabetes | 1,980 (est.) | Recruiting | Feb 2026 | Mar 2028 |
| ENLIGHTEN-4 | NCT07353931 | Knee osteoarthritis pain with obesity or overweight | 900 (est.) | Recruiting | Feb 2026 | Mar 2028 |
| ENLIGHTEN-3 | NCT07369011 | Obstructive sleep apnea with obesity or overweight | 800 (est.) | Recruiting | Feb 2026 | Mar 2028 |
| ENLIGHTEN-6 | NCT07392190 | Persistent obesity on a weekly incretin drug | 900 (est.) | Recruiting | Feb 2026 | Jun 2028 |
All five are randomized, double-blind and placebo-controlled, with once-weekly dosing, and their primary outcome is the percent change in body weight. ENLIGHTEN-1, -2 and -6 each have four eloralintide dose arms plus placebo, and ENLIGHTEN-3 and -4 are master protocols with two sub-studies each.
| Study | Who qualifies (headline criteria) | Extra primary outcome | Sites listed |
|---|---|---|---|
| ENLIGHTEN-1 | Adults with BMI 30 or more, or 27 or more with high blood pressure, dyslipidemia, sleep apnea or heart disease; stable weight for 90 days; at least one unsuccessful diet attempt; no diabetes | None | 158 |
| ENLIGHTEN-2 | Adults with type 2 diabetes on stable treatment for 90 days; BMI 27 or more; stable weight | None | 143 |
| ENLIGHTEN-3 | Adults with moderate to severe obstructive sleep apnea (apnea-hypopnea index 15 or more); BMI 27 or more; one sub-study for people unable or unwilling to use airway pressure therapy and one for people who use it | Apnea-hypopnea index | 115 |
| ENLIGHTEN-4 | Adults with knee osteoarthritis and BMI 27 or more; stable weight; at least one unsuccessful diet attempt; no diabetes | WOMAC pain score | 153 |
| ENLIGHTEN-6 | Adults on a stable weekly incretin drug who still have BMI 30 or more, or 27 or more with a complication (including type 2 diabetes) | None | 185 |
Common exclusions in the records include previous or planned weight-loss surgery or an endoscopic or device-based obesity procedure, and type 1 diabetes. The full criteria are on each registry page and change over time.
What each study is built to answer
- ENLIGHTEN-1 is the main obesity study without diabetes. It has the longest follow-up, with study completion estimated for July 2030.
- ENLIGHTEN-2 is the first to read out and covers type 2 diabetes, the same population as the EloraTZP phase 2b trial.
- ENLIGHTEN-3 and -4 test whether eloralintide improves sleep apnea severity and knee pain as well as weight. Retatrutide’s TRIUMPH-1 reported results in those same two conditions.
- ENLIGHTEN-6 asks whether eloralintide helps people whose weight has stopped falling on a weekly incretin drug, which is the add-on question.
Phase 2: five studies
| Study | NCT number | Population | Participants | Status | Started | Primary completion |
|---|---|---|---|---|---|---|
| Master protocol LY900038 | NCT06143956 | Multi-drug phase 2 platform (eloralintide is one appendix; size covers all drugs) | 1,481 (est.) | Recruiting | Nov 2023 | Sep 2027 |
| Phase 2 (Lancet) | NCT06230523 | Obesity or overweight without diabetes, versus placebo | 263 | Completed | Feb 2024 | May 2025 |
| EloraTZP phase 2b | NCT06603571 | Eloralintide and tirzepatide, alone or combined, with type 2 diabetes | 367 | Completed | Sep 2024 | Jul 2026 |
| Macupatide + eloralintide | NCT07215559 | Alone or combined, with type 2 diabetes | 200 (est.) | Active, not recruiting | Oct 2025 | Mar 2027 |
| Macupatide + eloralintide | NCT07589608 | Alone or combined, without type 2 diabetes | 400 (est.) | Recruiting | May 2026 | Sep 2027 |
The master protocol’s participant count covers all its investigational drugs, not eloralintide alone.
- The 263-person trial is the Lancet study, which reported -9% to -20% weight change at 48 weeks.
- The 367-person trial is the EloraTZP study, which reported -23.3% for the highest combination at 48 weeks.
- The two macupatide trials are testing eloralintide alone, macupatide alone and the pair, in people with and without type 2 diabetes. Primary completion is estimated for March and September 2027.
Phase 1: eleven studies
| Study | NCT number | Population | Participants | Status | Started | Primary completion |
|---|---|---|---|---|---|---|
| First-in-human | NCT05295940 | Single ascending dose in healthy adults and multiple ascending dose in adults with obesity or overweight | 148 | Completed | Mar 2022 | Jan 2024 |
| Phase 1 | NCT06345066 | Overweight and obese participants | 96 | Completed | Apr 2024 | Sep 2025 |
| Phase 1, Japan | NCT06297616 | Japanese participants with obesity or overweight | 128 | Completed | Apr 2024 | Nov 2025 |
| Phase 1 | NCT06916065 | Eloralintide with and without tirzepatide | 188 | Completed | Apr 2025 | Jan 2026 |
| Phase 1, China | NCT06916091 | Chinese participants with obesity or overweight | 30 | Completed | Apr 2025 | Sep 2025 |
| Phase 1, liver | NCT07401862 | Different levels of liver damage versus normal liver function | 36 (est.) | Recruiting | Feb 2026 | Mar 2027 |
| Phase 1, kidney | NCT07426380 | Renal impairment versus normal kidney function | 28 (est.) | Active, not recruiting | Feb 2026 | Oct 2026 |
| Phase 1 | NCT07665879 | Overweight or obesity | 115 (est.) | Recruiting | Jun 2026 | Aug 2027 |
| Phase 1 | NCT07701083 | Healthy participants | 58 (est.) | Active, not recruiting | Jul 2026 | Oct 2026 |
| Phase 1 | NCT07738614 | Obesity or overweight | 56 (est.) | Recruiting | Jul 2026 | Dec 2026 |
| Phase 1, women | NCT07808060 | Female participants with obesity or overweight | 34 (est.) | Recruiting | Sep 2026 | Jun 2027 |
Phase 1 studies establish safety, how the body handles the drug and how it behaves in specific groups. Several in this list matter for a future label: the liver and kidney studies show whether people with impaired organ function clear the drug differently, the Japanese and Chinese studies check whether results hold in other populations and the female-only study (started September 2026) looks at a group underrepresented in earlier phases.
Which studies have published results
| Study | What has been reported | Where |
|---|---|---|
| First-in-human (NCT05295940) | Single-dose safety and weight data in healthy adults; 12-week multiple-dose data in adults with obesity | Molecular Metabolism 2025; Diabetes, Obesity and Metabolism 2026 |
| Phase 2 (NCT06230523) | 48-week weight and safety results | The Lancet, November 2025 |
| EloraTZP phase 2b (NCT06603571) | Weight and HbA1c results for 10 arms, discontinuation rates | Lilly release, September 30, 2026 (full paper not yet seen) |
| All others | No results found in the sources I read | Check the registry |
Our guides report those results: what eloralintide is, trial results, side effects and EloraTZP.
How to read a registry entry
- Estimated or actual. Dates and participant counts marked estimated can change. “Actual” means it has happened.
- Primary completion versus study completion. Primary completion is when data for the main outcome are finished. Study completion is the end of all follow-up. A company can file after primary completion.
- Recruiting statuses. “Recruiting” means enrolling. “Active, not recruiting” means enrollment has closed and the study continues. “Completed” means it ended.
- Phases. Phase 1 studies safety and pharmacology. Phase 2 looks for a dose and a signal. Phase 3 confirms results in large groups and supports a filing.
- Master protocols. Some entries cover several sub-studies or drugs under one record.
How people find eloralintide trials
The registry at ClinicalTrials.gov lists every study and its locations, and Lilly’s trial site lists its own studies. Each record has a contact for each site. Anyone considering a trial should read the full eligibility list, understand that a study may assign placebo, and talk to their own clinician first. This page is not a recruitment channel, and Peptryn cannot enroll anyone or advise on joining.
What is missing from the registry
- No adolescent or pediatric study. The five phase 3 studies set a minimum age of 18, and I found no study in people under 18 (I did not check each phase 1 record).
- No head-to-head trial. No registered study compares eloralintide with semaglutide, tirzepatide, cagrilintide or retatrutide as the active comparator.
- No cardiovascular outcomes trial. None is registered for eloralintide that I could find.
- No oral formulation. All the registered studies I read use once-weekly injections.
- No expanded-access program. None turned up in my search.
What to expect next
| When | Event |
|---|---|
| Late 2026 | Phase 1 studies in kidney impairment and healthy participants reach primary completion (October 2026); EloraTZP phase 3 planned to start |
| 2027 | Liver impairment (March), first macupatide combination study (March), second (September) and the master protocol (September) reach primary completion |
| January to June 2028 | ENLIGHTEN-2, then -1, -3, -4 and -6 reach primary completion |
| 2030 | ENLIGHTEN-1 study completion (July) |
Our approval status guide turns those dates into an approval estimate, and our news log records changes as they happen.
Common questions
How many clinical trials of eloralintide are there?
ClinicalTrials.gov lists 21 Eli Lilly studies of eloralintide as of October 15, 2026: 11 phase 1, 5 phase 2 and 5 phase 3, with about 9,243 participants actual and planned.
Is eloralintide in phase 3?
Yes. Five phase 3 ENLIGHTEN studies are recruiting, and the first (ENLIGHTEN-2) started on December 15, 2025.
What is the ENLIGHTEN trial?
ENLIGHTEN is Lilly’s phase 3 program for eloralintide. It has five studies (1, 2, 3, 4 and 6) covering obesity without diabetes, obesity with type 2 diabetes, obstructive sleep apnea, knee osteoarthritis pain and persistent obesity on a weekly incretin drug.
How many people are in the eloralintide phase 3 trials?
About 5,615 are planned across the five studies: 1,980, 1,035, 900, 900 and 800.
When do the eloralintide phase 3 trials end?
Estimated primary completion dates run from January 2028 to June 2028, and ENLIGHTEN-1’s study completion is estimated for July 2030. Registry dates are estimates.
Has eloralintide been tested for sleep apnea or knee pain?
Not yet reported. ENLIGHTEN-3 (sleep apnea) and ENLIGHTEN-4 (knee osteoarthritis pain) are recruiting and add the apnea-hypopnea index and the WOMAC pain score as primary outcomes.
Can I join an eloralintide clinical trial?
Possibly, if you meet a study’s criteria and a site is near you. Search the registry and talk to your clinician. Peptryn does not recruit for or advise on trials.
Are there trials of eloralintide with tirzepatide?
Yes. The EloraTZP phase 2b trial (NCT06603571) finished in 2026, and a phase 1 study (NCT06916065) tested eloralintide with and without tirzepatide. Lilly plans phase 3 of a co-formulation by the end of 2026.
Who sponsors the eloralintide trials?
Eli Lilly and Company sponsors all 21 registered studies.
Where can I read the results of the eloralintide trials?
The phase 2 results are in The Lancet, the phase 1 results are in Molecular Metabolism and Diabetes, Obesity and Metabolism, and the EloraTZP results are in a Lilly release. See the table above.
Related: What is eloralintide? · Eloralintide approval status · EloraTZP · Eloralintide news · Eloralintide dosage · Amylin analogs · All eloralintide guides
Sources
All records retrieved from the ClinicalTrials.gov API on October 15, 2026.
- ClinicalTrials.gov. Search: eloralintide and search: LY3841136. Individual records are linked in the tables above.
- Eli Lilly. EloraTZP phase 2b results, September 30, 2026: PR Newswire.
- Billings LK, et al. Eloralintide phase 2. The Lancet 2025; DOI 10.1016/S0140-6736(25)02155-5.
- Briere DA, et al. Molecular Metabolism 2025; PMC12640043. Bhattachar S, et al. Diabetes, Obesity and Metabolism 2026; PMC12992164.
- Retatrutide, a triple hormone receptor agonist, for treatment of obesity (TRIUMPH-1). NEJM 2026; PubMed 42814954.
Editorial note: Peptryn sells research materials for laboratory use only. This guide is informational and is not medical advice. To report an error, use the contact page.
All products on peptryn.com are intended for laboratory research purposes only. They are not drugs, foods, dietary supplements or cosmetics, and they are not for human consumption, self-administration, or veterinary use. You must be 21 or older to buy. The information on this page has not been evaluated by the U.S. Food and Drug Administration and is not intended to diagnose, treat, cure, or prevent any disease.
